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Abstract 
Background 
Prognostic markers for risk-stratification of patients with gastrointestinal high-grade 
neuroendocrine carcinomas (GI-NECs) are lacking; we designed and validated a prognostic 
score for overall survival (OS). 
Methods 
Consecutive patients, diagnosed in five neuroendocrine specialist European Centres were 
included. Patients were divided into three cohorts: a training cohort (TC), an external 
validation cohort (EVC) and a prospective validation cohort (PVC). Prognostic factors were 
identified by using Log-rank test, Cox-regression and logistic regression analyses. The derived 
score was internally and externally validated. All statistical tests were two-sided.  
Results  
Of 395 patients screened, 313 were eligible (TC: 109 patients, EVC: 184 patients and PVC: 20 
patients). The derived prognostic score included five variables (presence of liver metastases, 
alkaline phosphatase (ALK), lactate dehydrogenase (LDH), ECOG performance status (PS) and 
Ki67). On multivariable analysis, the score was prognostic for OS (HR 1.86, 95%CI 1.47-2.35; 
p<0.001) and had good discrimination (C-index, 0.76) and calibration (mean error, 0.021; 
percentile 90, 0.037) in the TC. These results were validated in the EVC and PVC; in which it 
was able to prognosticate for OS when adjusted for other prognostic variables in the 
multivariable analysis (HR 1.85 (95%CI 1.27-2.71), p-value 0.001 and HR 4.51 (95%CI 1.87-
10.87), p-value 0.001, respectively). The score classified patients into two groups with 
incremental risk of death: group A (0-2 points; 181 patients (63.9%); median OS 19.4 months 
[95%CI 16.1-25.1]) and B (3-6 points; 102 patients (36.1%); median OS 5.2 months [95%CI 3.6-
6.9]).  
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Conclusion 
The GI-NEC score identifies two distinct patient cohorts; it provides a tool for clinicians when 
making treatment decisions and may be used as a stratification factor in future clinical trials. 
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Introduction  
Neuroendocrine malignancies from the gastrointestinal (GI) tract are relatively rare, although 
the incidence has been rising during recent years (1). Due to the impact on treatment strategy 
and survival, patients with neuroendocrine malignancies are classified according to both tumor 
morphology and assessment of proliferation according to WHO/ENETS guidelines. Morphology 
is classed as well- or poorly-differentiated; proliferation is assessed objectively by Ki-67 or 
mitotic count. Malignancies with a Ki-67 index >20% are considered high-grade 
neuroendocrine carcinomas (NEC-G3) (2-4). Well-differentiated tumours with a proliferation 
index of >20% have recently been described, so called NET-G3, as a discrete entity with clinical 
relevance (5, 6). 
Gastrointestinal NECs (GI-NECs) represent only 5-10% of all digestive neuroendocrine 
malignancies (7, 8) and arise mainly from the stomach, pancreas, or colon (9-11). They are 
usually diagnosed in advanced stages, when only palliative treatment is available. In contrast 
to well-differentiated GI-NETs (1), the median survival of patients with NECs (all stages) is 
clinically significantly shorter (estimated to be around 12-17 months) due to their aggressive 
natural history (6, 12). Distant disease is present at initial diagnosis in 57% of patients and 
impacts on survival: the median survival is 38 months (95% confidence interval [95% CI] 31-45 
months), 16 months (95% CI 15-17 months) and 5 months (95% CI 4.7-5.4 months) for patients 
with localised, locally advanced and metastatic disease, respectively (1, 13).  
Management of GI-NECs with advanced disease, is based on systemic cytotoxic 
chemotherapy due to high mitotic activity and rapid rate of disease progression. Current 
treatments are based on data from small cell lung cancer, such as cisplatin-etoposide or 
carboplatin-etoposide (14). First-line treatment for GI-NECs has remained unchanged since the 
early 1990s, when high tumour response rates were reported with etoposide-platinum 
combination (41-67%) (15). In addition, a number of small retrospective series have published 
results of other chemotherapy regimens (temozolomide-based (12, 16), taxane-based (12), 5-
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FU-based (17, 18) or topotecan (19)) after failure of platinum-etoposide therapy in patients 
with NECs (12, 16-20). Results from ongoing studies such as the ECOG-ACRIN 2142 trial 
(NCT02595424), which plans to randomise 126 patients diagnosed with NEC-G3 to first-line 
cisplatin/etoposide or capecitabine/temozolomide may clarify the most suitable treatment for 
this population of patients. 
Prognostic factors have been reported in small series, but have not been externally 
validated. These include Ki67 (12), Eastern Cooperative Oncology Group performance status 
(ECOG-PS) (12, 21), elevated lactate dehydrogenase (LDH) (12, 21), primary site (12, 21, 22), 
thrombocytosis (12) and tumour morphology (6). It is worth highlighting that survival reported 
between different series vary from 20 months (16, 18, 20) to 3 months (19) suggesting marked 
heterogeneity of the patient populations. In addition, clinicians are lacking tools to identify 
patients who may have longer survival and therefore may benefit from active treatment or 
inclusion in clinical trials. 
In this study, the aim was to design and validate a score prognostic for overall survival 
(OS) in patients with GI-NECs.  
 
Methods 
Study Design 
Three cohorts of patients were analysed: a Training Cohort (score was designed and internally 
validated), an External Validation Cohort (score was externally validated) and a Prospective 
Validation Cohort (score was prospectively validated). Approval for data collection was 
obtained independently by each one of the institutions involved as per local practice.  
Patients in cohort 1: Training cohort 
All consecutive patients diagnosed with GI-NEC between January 1997 and June 2014 at The 
Christie NHS Foundation Trust (Manchester, UK) were included in this retrospective cohort. 
Eligible patients where those with a diagnosis of GI-NEC (including patients with an unknown 
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primary in whom the primary tumor was suspected to be of GI origin) with a Ki67 >20%; and 
available survival data. Site of primary tumor was classified as foregut (oesophagus, stomach 
and proximal duodenum; excluding pancreas), midgut (distal duodenum, appendix and 
proximal colon), pancreas, hindgut (colon and rectum) or unknown primary according to 
clinical information available. Patients with ECOG-PS 4 and patients with mixed adeno-
neuroendocrine carcinoma were excluded. Demographic characteristics together with ECOG-
PS, stage (23, 24), primary GI tumour site, sodium, alkaline phosphatase (ALP), LDH and Ki67 at 
time of first diagnosis were collected for identification of prognostic factors and design of the 
prognostic score (25, 26). The primary end-point was OS, defined as the time between first 
diagnosis of NEC and death (or last follow-up with no death).  
Patients in cohort 2: External Validation Cohort 
Patients diagnosed with GI-NECs who were seen between April 2000 and December 2015 were 
identified retrospectively in five different European Countries (France, Belgium, Germany, 
Spain and UK) from centres with expertise in neuroendocrine malignancies. The same inclusion 
criteria as the Training Cohort were used and the same baseline and demographic 
characteristics were collected. Patients with missing data in any one of the items included in 
the score were excluded and considered ineligible. The primary end-point was OS. A sample 
size for the external validation was estimated to replicate the hazard ratio achieved by the 
score (as a discrete variable) in the multivariable analysis from the Training Cohort (HR 1.9); a 
minimum of 82 patients was required to externally validate the score (power: 80% and two-
tailed α-error: 0.05).  
Patients in cohort 3: Prospective Validation Cohort 
The Prospective Validation Cohort included all consecutive patients diagnosed with GI-NECs 
seen at The Christie NHS Foundation Trust between July 2014 and November 2015.  Patients 
were identified and data was collected prospectively. The same inclusion criteria and data 
8 
 
collection items as in the External Validation Cohort were applied; patients with missing data 
for any of the score items were excluded. The primary end-point was OS.  
Description of baseline characteristics and comparison between cohorts 
The median, with range and/or 95% CI, was calculated for continuous/discrete variables. 
Percentages were employed for distribution of categorical variables. Chi-square and T-Tests 
were used for comparison of baseline characteristics, as appropriate. Comparisons with p-
value ≤0.05 were considered statistically significant. 
Statistical analysis 
Statistical analysis was performed with Stata v.12 and RStudio packages. All statistical tests 
were two-sided.  
Design of the prognostic score (Training Cohort) 
Cox-regression, Kaplan-Meier, log-rank test and logistic regression were employed for 
identification of relevant factors impacting on OS. Proportionality of hazards assumption was 
assessed by graphic methods such as Log-log plot of survival and Kaplan–Meierobserved/ 
predicted survival plot. A maximum regression model including all the statistically significant 
variables in the univariate Cox-regression (defined as p-value ≤0.05) and previously-defined 
“variables of interest” (ECOG-PS, stage and Ki67) was designed. Treatment-related variables 
(such as administration of chemotherapy or radiological response) were excluded from the 
maximum regression model. The prognostic score included selected items from the maximum 
regression model, which were chosen by the allsets Stata command (selecting the model with 
lower Akaike Information Criterion (AIC), lower number of variables and without duplicated 
clinical information).  
Once the variables to be included in the prognostic score were identified, a score 
nomogram was built. First, continuous/discrete variables were categorised taking into account 
the most suitable cutoff according to Receiver Operating Characteristic (ROC) analysis for 
prediction of death. Second, Kaplan-Meier curve for prediction of OS, to confirm the tested 
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cutoff as the most informative one in terms of our primary end-point (OS). Finally, the 
punctuation for each item’s category was selected to be proportional to the hazard ratio 
achieved in the multivariable Cox-regression analysis.  
Accuracy of prediction of risk of survival: prognostic score compared to the maximum 
regression model (Training Cohort) 
The impact of the score on survival was confirmed by multivariable Cox-regression adjusted for 
other variables with known prognostic impact that were not included in the score. ROC curve 
comparison test (by comparison of Area Under the Curve (AUC)) was employed to compare 
the accuracy of prediction of survival at 3, 6, 9, 12, 18 and 24 months of the maximum model 
(considered the gold standard) and the prognostic score. Comparisons with p-values ≤0.05 
were considered statistically significant. 
Internal validation of the prognostic score (Training Cohort) 
Internal validation of the score was performed by Bootstrap-corrected Harrell Concordance 
Index (C-Index) calculation and Resampling Model Calibration. For interpretation of results of 
the C-Index, an index of 1 was considered to be perfectly discriminating, while a C-Index of 0.5 
was as good as a random estimation. 
External validation of the prognostic score (External and Prospective Validation Cohorts) 
The previously-designed score was applied to all patients in the External and Prospective 
Validation Cohorts. Cox-regression, Kaplan-Meier and log-rank tests were employed to identify 
factors impacting on OS. Multivariable Cox-regression analyses performed in the Training 
Cohort were reproduced to validate the impact of the score on OS.  
 
Results 
A total of 395 patients were identified and considered for eligibility. Of these, 313 patients 
with GI-NECs were eligible and included in the final analysis: Training Cohort (109 patients), 
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External Validation Cohort (184 patients) and Prospective Validation Cohort (20 patients) (See 
CONSORT diagram, Figure 1). 
Training Cohort: Patient’s baseline characteristics, prognostic factors and design of 
prognostic score 
The Training Cohort included 109 patients; baseline characteristics are summarised in Table1. 
By the end of follow-up, 83.5% of patients had died. The median estimated OS was 11.3 
months (95% CI 8.3-14.03).  
In addition to Ki67 (p-value 0.15) and ECOG-PS (p-value 0.046 for ECOG-PS 2 compared 
to ECOG-PS 0 ), which were previously defined as “variables of interest”; the following seven 
variables were found to be prognostic for OS by univariate Cox-regression analysis 
(Supplementary Table 1): stage (p-value 0.008 for metastatic stage compared to localized 
stage ), LDH (p-value <0.001), sodium (p-value 0.003), ALP (p-value <0.001), number of 
metastatic sites (p-value 0.021), presence of liver metastases (p-value <0.001) and presence of 
lung metastases (p-value 0.031). All these variables were included in the multivariable 
maximum regression model (Supplementary Table 1).  
Following analysis of 511 potential combinations, the most informative reduced model 
was selected to design the prognostic score. The selected reduced model included five 
variables (liver metastases, ECOG-PS, Ki67, LDH and ALP (Supplementary Table1) and had the 
following characteristics: AIC of 71.6, AUC of 0.839 and Hosmer-Lemeshow goodness-of-fit of 
0.977. Punctuation for each item was selected taking into account the HR from the 
multivariable analysis of the reduced model (Supplementary Table 1) and Figure 2).   
According to the sum of the five items, patients could be assigned a minimum of 0 to a 
maximum of 6 points. Risk of death, increased with each extra point added into the score 
(Supplementary Figure 1). Distribution of the prognostic score within TC population is 
summarized in Supplementary Table 2. 
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Internal Validation of the Score and Accuracy of prediction of risk of survival: prognostic 
score compared to the maximum regression model (Training Cohort) 
The score was internally validated showing good discrimination (C-Index of 0.76) and 
calibration (mean error 0.021; percentile 90 0.037; Figure 3). 
There was good accuracy for prediction of risk of survival when compared to the 
maximum regression model.  There were no differences between the prognostic score and the 
maximum regression model at 3, 6, 9, 12, 18 and 24 months (Supplementary Figure 2). 
Impact of the Score on OS 
Multivariable Cox-regression analysis, including the score as one of the variables (Table 2), was 
performed to assess its impact on survival when adjusted for other variables not included in 
the score such as sodium (independent prognostic factor identified during the score building 
process (Supplementary Table1) and stage (variable of interest). However lung metastases 
were another of the independent prognostic factor identified during the score building process 
(Supplementary Table1), this variable was not included in this multivariable analysis (Table 2), 
because this clinical information was already provided by other variables such as presence of 
liver metastases (included in the score) and stage (defined as variable of interest and therefore 
included in multivariable analysis). The score was an independent prognostic factor for OS (HR 
1.86, 95% CI 1.47-2.35; p-value <0.001) when the analysis was adjusted for other variables, 
such as stage and sodium (Table 2).  
External and Prospective Validation of the Score 
One hundred and seventy-eight and 20 patients were eligible for inclusion in the External 
Validation and in the Prospective Validation Cohorts, respectively. Baseline characteristics of 
these validation cohorts are shown in Table 1. Distribution of the prognostic score within these 
two populations of patients is summarized in Supplementary Table 2. 
The multivariable analysis (including the score as a prognostic variable) performed on 
the Training Cohort was replicated with each of the validation cohorts (Table 2). The score 
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remained an independent prognostic factor in both validation cohorts when adjusted for stage 
and sodium (previously showed to be prognostic variables in the univariate analysis): HR 1.85 
(95%CI 1.27-2.71; p-value 0.001) and HR 4.51 (95%CI 1.87-10.87; p-value 0.001), for EVC and 
PVC, respectively.  
Deriving the Score in clinical practice 
The prognostic score has been defined as a discrete variable, with a range from 0 to 6 points. 
For applicability in clinical practice, the score classified patients into two groups, with 
statistically significant differences in OS: group A (0-2 points; good prognosis patients; 181 
patients (63.9%); median OS 19.4 months [95%CI 16.1-25.1]) and group B (3-6 points; poor 
prognosis patients; 102 patients (36.1%); median OS 5.2 months [95%CI 3.6-6.9]) (Figure 4). 
When the multivariable analysis was repeated using the score as a dichotomised variable, the 
score (group A vs. B) was an independent prognostic factor in all patient cohorts (Table 2). 
Distribution of the prognostic score as a dichotomised variable within all populations of 
patients included in this is summarized in Supplementary Table 2. 
Receipt of chemotherapy had an impact on OS in both prognostic groups and was an 
independent positive prognostic factor (HR for patients receiving chemotherapy was 0.31 (95% 
CI 0.20-0.48); p-value <0.001) when adjusted for the prognostic score, stage and sodium in the 
multivariable analysis. This resulted in the following median OS: Group A treated with 
chemotherapy (129 patients, median OS 20.7 months (95% CI 16.7-26.4), Group A not treated 
with chemotherapy (24 patients, median OS 11.9 months (95% CI 4.6-81.1), Group B treated 
with chemotherapy (55 patients, median OS 8.1 months (95% CI 5.4-10.8), Group B not treated 
with chemotherapy (26 patients, median OS 2.1 months (95% CI 1.4-2.4).  
 
Discussion 
This study represents one of the largest series of patients diagnosed with high grade NECs to 
date (6, 12). High-grade NECs are known to consist of a heterogeneous population (27), in 
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whom prognosis depends on multiple factors (6, 12, 21), rather than unique variables; thus our 
interest in developing a prognostic score which would combine the impact of multiple 
variables (all objective, with the exception of performance status, which is subjective) in one 
unique measurement.  
The final GI-NEC Score showed prognostic impact, and its ability to identify a patient 
group with an inferior outcome was validated in an external cohort. This study constitutes a 
collaborative effort between five European Centres with recognised expertise in 
neuroendocrine malignancies giving credence to the results presented.  
The direct application of the GI-NEC Score identified two subgroups, a good prognosis 
(A) and poor prognosis (B) group with marked differences in OS. The magnitude of difference 
indicates that this score may not only have a role in determining prognosis and aiding 
treatment discussion between clinicians and patients, but may also influence clinical trial 
design with respect to patient stratification. 
Both prognostic groups benefitted from treatment with systemic chemotherapy. This 
benefit was more pronounced in group B patients (4-fold OS increase) than in group A patients 
(2-fold OS increase); however, differences due to patient selection bias cannot be excluded. 
Group B identified cases with behaviour similar to Small Cell lung Cancer (SCLC) in terms of 
prognosis, who may derive the greatest benefit from classical platinum plus etoposide 
chemotherapy combinations.  
The identification of two patient cohorts with apparently-different clinical courses 
highlights the need to consider different management strategies between them.  For instance, 
patients classified in group A, may be suitable for treatment options beyond platinum-
etoposide chemotherapy including alternative chemotherapy combinations for patients with a 
lower Ki67 or morphologically well-differentiated tumours (6, 12); or locoregional-directed 
therapy in cases with liver-predominant disease. In essence, although there is often urgency in 
starting platinum-etoposide chemotherapy in patients with GI-NEC, patients in group A may 
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benefit from case-by-case discussion within a NET multidisciplinary meeting regarding other 
treatment options. Furthermore, due to the absence of available clinical trials in this setting 
and the more-favourable survival of this particular group, these patients would be well-suited 
for early-phase trials. 
It is worth mentioning that the most suitable Ki67 cut-off for making clinical 
management decisions remains unclear. In the NORDIC retrospective study, it was suggested 
that a Ki67 cut-off of 55% was informative for choosing between platinum-based or 
temozolomide-based treatment (12). In contrast, the current series identified a different cut-
off (80%) as the most informative one with respect to OS (rather than treatment response). 
These results highlight that it is not advisable to make informed treatment decisions reliant on 
Ki67 alone.  Morphology should also be considered, as suggested by Heetfeld and colleagues 
(6). 
The Group A population still likely constitutes several different subgroups with 
differing molecular biology. These patients may derive benefit from further characterisation 
(28). A worldwide collaborative effort to better understand the nature of this pathology should 
be prioritised by the NET research community. 
On the other hand, patients classified in the poor prognosis group, in the absence of 
other alternatives, may derive the most benefit from therapy traditionally given to patients 
with SCLC. Our results suggest that in this poor-prognostic subgroup, there is an urgent priority 
to initiate chemotherapy treatment; which may be less pressing in Group A patients. 
This new prognostic tool may become a cornerstone in the stratification of patients for 
inclusion into clinical trials as a randomisation factor, allowing adjustment for multiple 
prognostic factors at once. This will allow for efficient reduction of stratification variables and 
may potentially reduce trial sample size and facilitate subgroup analysis. Trial design may also 
be influenced to develop distinct therapeutic approaches based on the clinical characteristics 
of both subgroups when evaluating and introducing new therapies. For instance, if we were to 
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design a trial with new immunotherapies (such us anti-PD1 targeted therapy, which has 
recently shown benefit in Merkel cell carcinoma (29)) a different approach may be considered 
in group B patients with induction chemotherapy before introducing the immunotherapy to 
achieve clinical control of the disease, thus optimising the use of chemotherapy. However, 
most patients in group A would not need this sequential approach.  
The limitations of this study are the ones which inherently apply to population data 
which are collected retrospectively (Training Cohort and External Validation Cohort), as shown 
by imbalances identified between patient cohorts (such as primary tumour site, Ki67 and 
median OS). Despite of the small sample size of the Prospective Validation cohort, the score 
retains its prognostic value; however, it would still require confirmation in a longer prospective 
series, ideally within a clinical trial. In addition, the depth of this analysis is limited to the use of 
clinical data; i.e. chromogranin-A and neurone-specific enolase, were not included due to data 
unavailability. The absence of single central pathology review is attenuated by the 
documented expertise of these centres and their pathology departments. The fact that 
patients with no survival data or at least one of the score items missing were excluded from 
the EVC and PVC could introduce a selection bias. Finally, tumour morphology (well 
differentiated high grade vs. poorly differentiated high grade) was not incorporated into this 
score due to non-availability of this information for the majority of patients.  Patients with the 
emerging entity of NET-G3 are most likely to be included in Group A; the high Ki67 cut-off 
employed in this study (80%) may negate this limitation due to the low rate of patients with 
well-differentiated morphology who would be expected to have a Ki67 of >80% (6). 
In summary, in this study, the GI-NEC Score was designed and validated for patients 
with GI-NECs for prognostication of OS, as a tool to aid clinician selection of patients for 
treatment or clinical trial inclusion. This score could also be incorporated as a stratification 
factor in future comparative trials, to assist adjustment for prognostic factors and secure 
comparability between arms. 
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Table 1: Baseline characteristics of cohort of patients included in the study*  
Variable 
Training Cohort (n=109) External Validation Cohort (n=184) Prospective Validation Cohort (n=20) 
N (%) N (%) N (%) 
Age, Median (range) 67.7 (16.3-84.1) 59.1 (22.2-85.5) 67.7 (22.9-82.7) 
Gender    
Male 67 (61.5) 115 (62.5) 15 (75.0) 
Female 42 (38.5) 69 (37.5) 5 (25.0) 
Stage    
Localised 11 (10.1) 9 (4.9) 2 (10.0) 
Locally advanced 7 (6.4) 26 (14.1) 3 (15.0) 
Metastatic 91 (83.5) 149 (80.9) 15 (75.0) 
Site of primary tumour    
Foregut 21 (19.3) 33 (17.9) 1 (5.0) 
Midgut 5 (4.6) 8 (4.4) 4 (20.0) 
Pancreas 20 (18.4) 75 (40.8) 4 (20.0) 
Hindgut 31 (28.4) 31 (16.9) 5 (25.0) 
Unknown primary 32 (29.4) 37 (20.1) 6 (30.0) 
Site of metastases    
Median (range) 1 (0-4) 1 (0-6) 1 (0-4) 
Liver (Yes) 70 (64.2) 123 (66.9) 12 (60.0) 
Lungs (Yes) 10 (9.2) 12 (6.5) 3 (15.0) 
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Lungs (unknown) 0 79 0 
Sodium, mmol/L    
Median (range) 139 (124-145) 138 (129-144) 139.5 (133-143) 
Unknown  0 115 0 
Alkaline Phosphatase, IU/l    
Median (range) 109 (45-2.03x103) 129.5 (30-2.3x103) 103 (64-2.04x103) 
Unknown  14 0 0 
Lactate dehydrogenase, IU/l    
Median (range) 463 (258-11.1x103) 347 (107-3.8x103) 450 (258-1.4x103) 
Unknown 17 0 0 
Ki67, %    
Median (range) 70 (60-70) 55 (50-62) 80 (41-80) 
Unknown 15 0 0 
ECOG Performance Status    
0 28 (25.9) 65 (35.3) 3 (15.0) 
1 57 (52.8) 82 (44.6) 10 (50.0) 
2 17 (15.7) 27 (14.7) 3 (15.0) 
3 6 (5.6) 10 (5.4) 4 (20.0) 
Unknown 1 (0.1) 0 (0.0) 0 (0.0) 
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Palliative Chemotherapy    
Yes 76 (69.7) 118 (64.1) 14 (70.0) 
Unknown  0 (0.0) 49 (26.6) 0 (0.0) 
Follow-up, median (95% CI) 9.7 (7.02-12.3) 11.4 (8.6-14.7) 5.01 (3.5-12.7) 
Status, dead 91 (83.5) 127 (69.1) 11 (55.0) 
Overall survival, median (95% CI) 11.3 (8.3-14.03) 16.04 (13.7-19.03) 10.1 (3.5-nr) 
* Overall survival medians are estimated with Kaplan-Meier. Normal ranges for laboratory results were as follows sodium 135-145 mmol/L; alkaline 
phosphatase 25-110 IU/L; lactate dehydrogenase 200-550 IU/L. Nr=not reached, CI=confidence interval. 
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Table 2: Multivariable prognostic analysis for overall survival (Cox regression). *  
 
 
Training Cohort External Validation Cohort Prospective Validation Cohort All Cohorts 
HR (95% CI) P-value† HR (95% CI) P-value† HR (95% CI) P-value† HR (95% CI) P-value† 
Score as a discrete variable         
Stage         
Localised 1 (Ref) - 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Locally advanced 0.88 (0.16 - 4.91) 0.88 0.81 (0.19-3.36) 0.77 0.17 (0.01-5.63) 0.32 0.84 (0.32-2.19) 0.88 
Metastatic 2.11 (0.73 – 6.12) 0.17 0.91 (0.24-3.45) 0.88 0.11 (0.01-1.73) 0.12 1.28 (0.59-2.73) 0.45 
Sodium, continuous variable 1.02 (0.95 - 1.08) 0.64 0.97 (0.86-1.09) 0.61 0.77 (0.57-1.05) 0.11 1.01 (0.96-1.06) 0.72 
Score, discrete variable 1.86 (1.47 - 2.35) < 0.001 1.85 (1.27-2.71) 0.002 4.51 (1.87-10.87) 0.001 1.95 (1.62-2.36) <0.001 
Score as a dichotomised variable         
Stage         
Localised 1 (Ref) - 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Locally advanced 1.29 (0.23 - 7.24) 0.77 0.82 (0.21-3.38) 0.93 0.32 (0.02-7.22) 0.47 0.88 (0.34-2.29) 0.79 
Metastatic 2.57 (0.89 – 7.46) 0.08 1.27 (0.35-4.61) 0.62 0.15 (0.01-2.16) 0.16 1.64 (0.77-3.51) 0.20 
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Sodium, continuous variable 0.99 (0.93-1.06) 0.79 0.97 (0.86-1.09) 0.77 0.87 (0.67-1.13) 0.29 0.99 (0.94-1.04) 0.74 
Score         
Group A (0-2 points) 1 (Ref) - 1 (Ref) - 1 (Ref) - 1 (Ref) - 
Group B (3-6 points) 3.61 (1.96-6.65) <0.001 3.39 (1.57-7.31) <0.001 14.33 (2.28 -90.13) 0.005 3.94 (2.53-6.13) <0.001 
* Only patients with all data available for all the variables included in the multivariable analysis were included: Training Cohort (79 patients), External 
validation Cohort (63 patients), Prospective Validation Cohort (20 patients) and all cohorts (162 patients). CI=confidence interval; HR=hazard ratio. 
† [Please name the statistical test used to calculate the P values and say if that test was two-sided.] 
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FIGURES 
Figure 1: CONSORT diagram: patient flow for each cohort of patients included in the design 
and validation of the prognostic score. N: number of patients; GI: gastrointestinal; NEC: 
neuroendocrine carcinoma (high grade); ECOG-PS: Eastern Cooperative Oncology Group 
performance status; OS: overall survival. 
Figure 2: Nomogram for calculation of the prognostic score. Example: patient with ECOG-PS of 
1 (0 points), liver metastases (1 point), ALP of 70 (0 points), LDH of 840 (1 point) and Ki67 of 75 
(0 points) scores a total of 2 points. ALP: alkaline phosphatase; LDH: lactate dehydrogenase, 
ECOG-PS: Eastern Cooperative Oncology Group performance status. 
Figure 3: The Prognostic Score showed good calibration (Mean (error) = 0.021; Percentile 90= 
0.037).  
Figure 4: Prognostic score defining two populations of patients with statistically significant 
differences in overall survival: this is shown when all cohorts are analysed together (A) and 
also in each cohort separately: Training Cohort (B), External Validation Cohort (C) and 
Prospective Validation Cohort (D). Log-rank test p-value is provided, for multivariable Cox 
Regression p-value please refer to Table 2. Only those patients with available data for 
calculation of the GI-NEC Score (all items were required) and survival data available are 
represented in these graphics, represented by 283 patients out of the total 313 patients 
included in All Cohorts, 79 out of 109 in the Training Cohort, 184 out of 184 in the External 
Validation Cohort and 20 out of 20 in the patients from the Prospective Validation Cohort), 
patients with at least one of the items or survival data missing (i.e. 30 patients from the 
Training Cohort (B) and therefore 30 patients from the All Cohorts (A)) are excluded.  All 
statistical tests were two-sided. 
